Inhibrx Biosciences recently reported updated interim Phase 1/2 data showing that ozekibart (INBRX-109) plus FOLFIRI produced a 20% objective response rate, 5.5-month median progression-free survival ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. He was previously ...

Decoding molecular, clinico-pathological, and outcome differences between early-onset (EO, 50 years) and late-onset (LO, ≥50 years) mismatch repair deficient (dMMR)/microsatellite instability-high ...

Resection of liver metastases remains the only treatment with curative potential for metastatic colorectal cancer to the liver, but unfortunately few patients are eligible for the surgery. For ...

Thermal ablation demonstrated noninferiority to surgical resection for small colorectal liver metastases, with comparable overall survival and local control outcomes. The COLLISION trial showed ...

Doublet chemotherapy with fluoropyrimidine (FP) and oxaliplatin (OX) plus bevacizumab (BEV) is a standard regimen for unresectable metastatic colorectal cancer (MCRC). However, the efficacy of adding ...

The risk of disease progression or death was reduced by 79% with nivolumab/ipilimumab compared with chemotherapy. The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in ...

Please provide your email address to receive an email when new articles are posted on . Y-90 resin microspheres are the only approved radioembolization therapy for hepatic cellular carcinoma and ...

Detailed price information for Catalyst Pharm Inc (CPRX-Q) from The Globe and Mail including charting and trades.